SEC Form 4 · accession 0001209191-17-024743
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen Susan Kim
Officer — EVP, Business Development
Period of report
Apr 3, 2017
Accepted (ET)
Apr 4, 2017 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 3, 2017 | M | 2,400 | $53.90 | A | 21,064 | D | |
| Common Stock | Apr 3, 2017 | S | 2,400 | $81.80 | D | 18,664 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $53.90 | Apr 3, 2017 | M | 2,400 | D | — | Dec 16, 2024 | Common Stock | 2,400 | 158,901 | D |
Explanation of responses
- F125% of the 180,000 shares subject to the stock option vested and became exercisable on November 10, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.